Targeting myeloid cells to improve cancer immune therapy

Tumor immunosuppression remains a major barrier to effective cancer immunotherapy and is often driven by the immunoregulatory activities of innate immune cells, such as myeloid cells within the tumor microenvironment (TME). Myeloid populations—including tumor-associated macrophages (TAMs), dendritic...

詳細記述

書誌詳細
出版年:Frontiers in Immunology
主要な著者: Hui Chen, Zihan Xu, Judith Varner
フォーマット: 論文
言語:英語
出版事項: Frontiers Media S.A. 2025-07-01
主題:
オンライン・アクセス:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623436/full